AZD0305 / LaNova Medicines Limited, AstraZeneca - LARVOL DELTA

AZD0305: Data from P1/2 trial (NCT06106945) for r/r multiple myeloma in 2026 (AstraZeneca) - Q1 2025 Results

P1/2 data • Hematological Malignancies • Multiple Myeloma • Oncology

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=99 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Nov 2025 ➔ Aug 2026 | Trial primary completion date: Nov 2025 ➔ Aug 2026

Monotherapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (ASH 2024) - P1/2 | "The GPRC5D bispecific T-cell-engager talquetamab was conditionally approved recently by the FDA and EMA for the treatment of RRMM in adults with at least 4 prior lines of therapy. Secondary endpoints include but are not limited to objective response rate, duration of response, progression free survival, pharmacokinetics of AZD0305 and immunogenicity of AZD0305. This study is currently recruiting patients for phase I in North America, Europe, Asia and Australia."

Clinical • P1/2 data • Cardiovascular • Chronic Obstructive Pulmonary Disease • Hematological Malignancies • Immunology • Interstitial Lung Disease • Multiple Myeloma • Oncology • Pain • Pulmonary Disease • Respiratory Diseases

AZD0305: Data from P1/2 trial (NCT06106945) for r/r multiple myeloma in H2 2025 (AstraZeneca) - H1 & Q2 2024 Results

P1/2 data • Hematological Malignancies • Multiple Myeloma • Oncology

AZD0305: Data from P1/2 trial (NCT06106945) for r/r multiple myeloma in 2025 (AstraZeneca) - Q4 & FY2023 Results

P1/2 data • Hematological Malignancies • Multiple Myeloma • Oncology

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: AstraZeneca | N=64 ➔ 84

Combination therapy • Enrollment change • Monotherapy • Hematological Malignancies • Multiple Myeloma • Oncology

A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=64 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: LaNova Medicines Limited | N=380 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Hematological Malignancies • Multiple Myeloma • Oncology

A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=64 | Not yet recruiting | Sponsor: AstraZeneca

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate (BioSpace) - "Nina Shah...said: 'We are pleased to have the opportunity to advance the development of LM-305, a novel GPRC5D-targeting antibody drug conjugate (ADC), as a potential new treatment option for relapsed/refractory multiple myeloma. LM-305 advances our leadership in ADCs and enriches our growing Haematology pipeline, helping us deliver against our broader ambition to transform clinical outcomes for patients living with blood cancers.'"

Media quote

LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate (PRNewswire) - "LaNova Medicines...announced today it has entered into an exclusive license agreement with AstraZeneca...for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D). Under the terms of the licensing agreement, AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305. LaNova Medicines is eligible to receive an upfront and near-term payments of up to $55 million and additional development and commercial milestone payments of up to $545 million, as well as tiered royalties on net sales worldwide....'With the potential to become a first-in-class GPRC5D-directed ADC for multiple myeloma, LM-305 exemplifies our innovative and robust platform for ADC development'."

Licensing / partnership • Hematological Malignancies • Multiple Myeloma • Oncology

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases (clinicaltrials.gov) - P1/2 | N=380 | Not yet recruiting | Sponsor: LaNova Medicines Limited

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology